iN2011-k74

iN2011-k74 is an investigational small molecule drug candidate being developed by **Daewoong Pharmaceutical** and its subsidiary **Great Bear Pharmaceutical** for the treatment of **sensorineural hearing loss (SNHL)**. As a New Chemical Entity (NCE), the compound is designed to address the underlying biological causes of hearing impairment, which typically involves the damage or loss of auditory hair cells in the cochlea. While the specific molecular target has not been publicly disclosed in pipeline summaries, the program focuses on pharmacological intervention to potentially regenerate or protect these sensory cells. The asset is currently in the early stages of development, representing a novel approach in a therapeutic area with significant unmet needs and few approved pharmacological treatments.